PWP1在肝細(xì)胞癌中過表達(dá)，促進(jìn)肝癌細(xì)胞增殖

2024年6月，生物化學(xué)與分子生物學(xué)系，重大疾病共機(jī)制研究國家重點(diǎn)實(shí)驗(yàn)室，基礎(chǔ)醫(yī)學(xué)院中國醫(yī)學(xué)科學(xué)院，北京協(xié)和醫(yī)科大學(xué)基礎(chǔ)醫(yī)學(xué)院，北京100005，內(nèi)蒙古醫(yī)科大學(xué)附屬醫(yī)院中國臨床醫(yī)學(xué)研究中心，內(nèi)蒙古醫(yī)學(xué)細(xì)胞生物學(xué)重點(diǎn)實(shí)驗(yàn)室（a Department of Biochemistry and Molecular Biology, State Key Laboratory of Common Mechanism Research for Major Diseases, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, 100005, China b Clinical Medical Research Center of the Affiliated Hospital, Inner Mongolia Medical University, Inner Mongolia Key Laboratory of Medical Cell

Biology, 1 Tong Dao Street, Hohhot, 010050, Inner Mongolia, China ）Wei Song.a 研究團(tuán)隊(duì)在《Heliyon》上發(fā)表論文：

“PWP1 is overexpressed in hepatocellular carcinoma and facilitates liver cancer cell proliferation”

“PWP1在肝細(xì)胞癌中過表達(dá)，促進(jìn)肝癌細(xì)胞增殖”

Abstract：

Identification of novel biomarkers for prediction of disease course and prognosis is needed to reduce morbidity of liver hepatocellular carcinoma (LIHC/HCC) patients. Although dysregulated Periodic tryptophan protein 1 homolog (PWP1/endonuclein) expression has been detected in several tumors, the potential regulatory effect of PWP1 on LIHC remains uncertain. Here we evaluated the expression of PWP1 using multiple online platforms, and demonstrated that PWP1 upregulation was consistently observed in LIHC relative to non-tumor liver tissues and correlated with unfavorable prognosis. Moreover, HCC prognosis was significantly influenced by the

methylation status of various CpG sites in the PWP1 gene. Lastly, we provide direct evidence that PWP1 acts as a driver of HCC progression by showing that siRNA-mediated PWP1 silencing significantly suppressed HCC cell proliferation in vitro. These data strongly suggest that PWP1 silencing may be an effective therapeutic strategy to treat LIHC.

摘要：

為了降低肝細(xì)胞癌(LIHC/HCC)患者的發(fā)病率，需要鑒定新的生物標(biāo)志物來預(yù)測病程和預(yù)后。盡管在幾種腫瘤中檢測到周期性色氨酸蛋白1同源物(PWP1/內(nèi)核素)表達(dá)異常，但PWP1對LIHC的潛在調(diào)節(jié)作用仍不確定。本研究中，研究人員利用多個(gè)在線平臺評估了PWP1的表達(dá)，結(jié)果表明，相對于非腫瘤肝組織，PWP1在LIHC中一致表達(dá)上調(diào)，并與不良預(yù)后相關(guān)。此外，HCC預(yù)后受PWP1基因中各種CpG位點(diǎn)甲基化狀態(tài)的顯著影響。最后，科研人員通過sirna介導(dǎo)的PWP1沉默在體外顯著抑制HCC細(xì)胞增殖，提供了PWP1作為HCC進(jìn)展驅(qū)動(dòng)因素的直接證據(jù)。這些數(shù)據(jù)強(qiáng)烈提示PWP1沉默可能是治療LIHC的有效治療策略。

該論文中，人肝癌細(xì)胞系(Huh7、HepG2、PLC和SMMC7721)細(xì)胞的體外培養(yǎng)是使用Ausbian特級胎牛血清完成的。欲了解或購買Ausbian特級胎牛血清可以聯(lián)系北京締一生物400-166-8600.